The Implications of 7-dehydrosterol-7-reductase Deficiency (Smith-Lemli-Opitz Syndrome) to Neurosteroid Production
Overview
Affiliations
Smith-Lemli-Opitz syndrome (SLOS) is an autosomal recessive, multiple malformation/mental retardation syndrome with an estimated incidence among individuals of European ancestry of 1 in 20000 to 1 in 30000. It is caused by inactivity of the enzyme 7-dehydrosterol-delta(7)-reductase, which catalyses the terminal transformation in cholesterol synthesis. Patients show not only an increased level of 7-dehydrocholesterol in blood and tissues, but also increased 8-dehydrocholesterol because of the presence of an active delta(8)-delta(7) isomerase. A major consequence of these biochemical abnormalities is the alteration of normal embryonic and fetal somatic development causing postnatal abnormalities of growth, learning, language and behavior. While deficient cholesterol during early development is the primary cause of central nervous system (CNS) abnormalities and retardation, we questioned whether neurosteroids could also be involved since they can have a profound influence on behavioral characteristics. Disordered neurosteroidogenesis would be expected in SLOS and could be caused by a deficiency in classical neurosteroid synthesis secondary to cholesterol deficiency, or by synthesis from 7- and 8-dehydrocholesterol of novel neurosteroids with delta(7) or delta(8) unsaturation which may have altered activity compared with conventional neurosteroids. In particular we sought analogues of dehydroepiandrosterone sulfate, pregnenolone sulfate and the pregnanolone epimers. We targeted urine from post-pubertal females, as this type of sample would be most likely to yield identifiable amounts of the pregnanolone metabolites of progesterone. Analysis by GC/MS of urinary steroids excreted by post-pubertal females confirmed the presence of neurosteroid-like compounds in SLOS patient's urine. Even though the new neuroactive steroids identified were unlikely to have been formed in the brain, it is likely that mechanisms for their synthesis are operable in this organ.
Untargeted Metabolomics for Autism Spectrum Disorders: Current Status and Future Directions.
Glinton K, Elsea S Front Psychiatry. 2019; 10:647.
PMID: 31551836 PMC: 6746843. DOI: 10.3389/fpsyt.2019.00647.
Mouro F, Miranda-Lourenco C, Sebastiao A, Diogenes M Front Neurosci. 2019; 13:680.
PMID: 31333401 PMC: 6614559. DOI: 10.3389/fnins.2019.00680.
Gillberg C, Fernell E, Kocovska E, Minnis H, Bourgeron T, Thompson L Autism Res. 2017; 10(6):1022-1044.
PMID: 28401679 PMC: 5485071. DOI: 10.1002/aur.1777.
Effect of psychotropic drug treatment on sterol metabolism.
Korade Z, Liu W, Warren E, Armstrong K, Porter N, Konradi C Schizophr Res. 2017; 187:74-81.
PMID: 28202290 PMC: 5554466. DOI: 10.1016/j.schres.2017.02.001.
Pathogenesis, Epidemiology, Diagnosis and Clinical Aspects of Smith-Lemli-Opitz Syndrome.
Bianconi S, Cross J, Wassif C, Porter F Expert Opin Orphan Drugs. 2015; 3(3):267-280.
PMID: 25734025 PMC: 4343216. DOI: 10.1517/21678707.2015.1014472.